|
1
|
Benjamin EJ, Blaha MJ, Chiuve SE, Cushman
M, Das SR, Deo R, de Ferranti SD, Floyd J, Fornage M, Gillespie C,
et al: Heart disease and stroke statistics-2017 update: A report
from the American Heart Association. Circulation. 135:e146–e603.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jennings RB, Sommers HM, Smyth GA, Flack
HA and Linn H: Myocardial necrosis induced by temporary occlusion
of a coronary artery in the dog. Arch Pathol. 70:68–78.
1960.PubMed/NCBI
|
|
3
|
Jordan JE, Zhao ZQ and Vinten-Johansen J:
The role of neutrophils in myocardial ischemia-reperfusion injury.
Cardiovasc Res. 43:860–878. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lesnefsky EJ, Chen Q, Tandler B and Hoppel
CL: Mitochondrial dysfunction and myocardial ischemia-reperfusion:
Implications for novel therapies. Annu Rev Pharmacol Toxicol.
57:535–565. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ferdinandy P, Hausenloy DJ, Heusch G,
Baxter GF and Schulz R: Interaction of risk factors, comorbidities,
and comedications with ischemia/reperfusion injury and
cardioprotection by preconditioning, postconditioning, and remote
conditioning. Pharmacol Rev. 66:1142–1174. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Drucker DJ: The biology of incretin
hormones. Cell Metab. 3:153–165. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Theodorakis MJ, Carlson O, Michopoulos S,
Doyle ME, Juhaszova M, Petraki K and Egan JM: Human duodenal
enteroendocrine cells: Source of both incretin peptides, GLP-1 and
GIP. Am J Physiol Endocrinol Metab. 290:E550–E559. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Holst JJ, Deacon CF, Vilsboll T, Krarup T
and Madsbad S: Glucagon-like peptide-1, glucose homeostasis and
diabetes. Trends Mol Med. 14:161–168. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sonne DP, Engstrom T and Treiman M:
Protective effects of GLP-1 analogues exendin-4 and GLP-1(9–36)
amide against ischemia-reperfusion injury in rat heart. Regul Pept.
146:243–249. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Noyan-Ashraf MH, Momen MA, Ban K, Sadi AM,
Zhou YQ, Riazi AM, Baggio LL, Henkelman RM, Husain M and Drucker
DJ: GLP-1R agonist liraglutide activates cytoprotective pathways
and improves outcomes after experimental myocardial infarction in
mice. Diabetes. 58:975–983. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bose AK, Mocanu MM, Carr RD, Brand CL and
Yellon DM: Glucagon-like peptide 1 can directly protect the heart
against ischemia/reperfusion injury. Diabetes. 54:146–151. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Deacon CF, Johnsen AH and Holst JJ:
Degradation of glucagon-like peptide-1 by human plasma in vitro
yields an N-terminally truncated peptide that is a major endogenous
metabolite in vivo. J Clin Endocrinol Metab. 80:952–957. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Eng J, Kleinman WA, Singh L, Singh G and
Raufman JP: Isolation and characterization of exendin-4, an
exendin-3 analogue, from Heloderma suspectum venom. Further
evidence for an exendin receptor on dispersed acini from guinea pig
pancreas. J Biol Chem. 267:7402–7405. 1992.PubMed/NCBI
|
|
14
|
Mikkola K, Yim CB, Fagerholm V, Ishizu T,
Elomaa VV, Rajander J, Jurttila J, Saanijoki T, Tolvanen T, Tirri
M, et al: 64Cu- and 68Ga-labelled
[Nle(14),Lys(40)(Ahx-NODAGA)NH2]-exendin-4 for pancreatic beta cell
imaging in rats. Mol Imaging Biol. 16:255–263. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wild D, Behe M, Wicki A, Storch D, Waser
B, Gotthardt M, Keil B, Christofori G, Reubi JC and Mäcke HR:
[Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for
glucagon-like peptide-1 (GLP-1) receptor targeting. J Nucl Med.
47:2025–2033. 2006.PubMed/NCBI
|
|
16
|
Sowa-Staszczak A, Pach D, Mikolajczak R,
Mäcke H, Jabrocka-Hybel A, Stefańska A, Tomaszuk M, Janota B,
Gilis-Januszewska A, Małecki M, et al: Glucagon-like peptide-1
receptor imaging with [Lys40(Ahx-HYNIC-99mTc/EDDA)NH2]-exendin-4
for the detection of insulinoma. Eur J Nucl Med Mol Imaging.
40:524–531. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kiesewetter DO, Gao H, Ma Y, Niu G, Quan
Q, Guo N and Chen X: 18F-radiolabeled analogs of exendin-4 for PET
imaging of GLP-1 in insulinoma. Eur J Nucl Med Mol Imaging.
39:463–473. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gao H, Kiesewetter DO, Zhang X, Huang X,
Guo N, Lang L, Hida N, Wang H, Wang H, Cao F, et al: PET of
glucagonlike peptide receptor upregulation after myocardial
ischemia or reperfusion injury. J Nucl Med. 53:1960–1968. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kiesewetter DO, Guo N, Guo J, Gao H, Zhu
L, Ma Y, Niu G and Chen X: Evaluation of an [(18)F]AlF-NOTA analog
of exendin-4 for imaging of GLP-1 receptor in insulinoma.
Theranostics. 2:999–1009. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Silverman J, Mark A and Murthy S: The
Iacuc Handbook. Iacuc Handbook; 2000
|
|
21
|
Eltzschig HK and Eckle T: Ischemia and
reperfusion-from mechanism to translation. Nat Med. 17:1391–1401.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Timmers L, Henriques JP, de Kleijn DP,
Devries JH, Kemperman H, Steendijk P, Verlaan CW, Kerver M, Piek
JJ, Doevendans PA, et al: Exenatide reduces infarct size and
improves cardiac function in a porcine model of ischemia and
reperfusion injury. J Am Coll Cardiol. 53:501–510. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dawwas GK, Smith SM and Park H: Risk of
heart failure hospitalization among users of dipeptidyl peptidase-4
inhibitors compared to glucagon-like peptide-1 receptor agonists.
Cardiovasc Diabetol. 17:1022018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Miller PW, Long NJ, Vilar R and Gee AD:
Synthesis of 11C, 18F, 15O, and 13N radiolabels for positron
emission tomography. Angew Chem Int Ed Engl. 47:8998–9033. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
McBride WJ, D'Souza CA, Sharkey RM,
Karacay H, Rossi EA, Chang CH and Goldenberg DM: Improved 18F
labeling of peptides with a fluoride-aluminum-chelate complex.
Bioconjug Chem. 21:1331–1340. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gao H, Niu G, Yang M, Quan Q, Ma Y, Murage
EN, Ahn JM, Kiesewetter DO and Chen X: PET of insulinoma using
(1)(8)F-FBEM-EM3106B, a new GLP-1 analogue. Mol Pharm. 8:1775–1782.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xu Y, Pan D, Xu Q, Zhu C, Wang L, Chen F,
Yang R, Luo S and Yang M: Insulinoma imaging with glucagon-like
peptide-1 receptor targeting probe (18)F-FBEM-Cys (39)-exendin-4. J
Cancer Res Clin Oncol. 140:1479–1488. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Korner M, Stockli M, Waser B and Reubi JC:
GLP-1 receptor expression in human tumors and human normal tissues:
Potential for in vivo targeting. J Nucl Med. 48:736–743. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nikolaidis LA, Mankad S, Sokos GG, Miske
G, Shah A, Elahi D and Shannon RP: Effects of glucagon-like
peptide-1 in patients with acute myocardial infarction and left
ventricular dysfunction after successful reperfusion. Circulation.
109:962–965. 2004. View Article : Google Scholar : PubMed/NCBI
|
